Insmed Incorporated

NASDAQ:INSM

Biotechnology

Healthcare
$119.80 -2.77%

-$2.73 today

Market cap
$26.28B
Beta
0.77
P/E (TTM)
-17.4
EPS (TTM)
-$5.49
52W Low $90.39High $212.75

Volume 1.94M

Average 3.31M

INSM Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Insmed IncorporatedNASDAQ: INSM

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $210.03M rose 18.5% year over year, behind the +30.4% change in trailing-twelve-month research & development. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +24.7% a year.

Context

  • Research & development amounted to 127.2% of revenue in FY2025, down 37.4 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +18.5% toward the trailing-twelve-month pace of +30.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$210.03M+0.3% QoQ
Last fiscal yearDec 2025
$771.09M+28.9% YoY
LTMJun 2026
$860.85M+30.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.5%——
1 year+28.9%——
3-year CAGR+24.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
771.09M USD
Year-over-year change
+28.9%
4-year CAGR
+29.7%

Research & Development vs competitors

How INSM compares with its peers on the latest reported figures

  • INSM's LTM Jun 2026 research & development of $860.85M is the highest of the 4 companies compared; the peer median is $55.75M.
  • Its year-over-year change of +30.4% is the 2nd highest of 4, against a peer median of +6.0%.
  • Research & development amounts to 75.7% of revenue for INSM, versus a peer median of 17.5%.
INSM Competitors Peer median
Research & Development for INSM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INSMInsmed IncorporatedLTM Jun 2026$860.85M +30.4%+24.7%75.7%
UTHRUnited Therapeutics CorporationLTM Jun 2026$551.5M +6.0%+19.4%17.5%
LQDALiquidia CorporationLTM Jun 2026$55.75M +34.8%+26.4%12.4%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$31.39M -21.6%-18.9%28.6%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding INSM) $55.75M+6.0%+19.4%17.5%

Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue188.46M245.36M305.21M363.71M606.42M
Cost of Revenue44.15M55.13M65.57M85.74M124.88M
Gross Profit144.31M190.23M239.64M277.97M481.55M
Gross Margin76.6%77.5%78.5%76.4%79.4%
Research & Development272.74M397.52M571.01M598.37M771.09M
Selling, General & Admin234.27M265.78M344.5M461.12M701.17M
Operating Expenses519.4M647.55M949.26M1.16B1.66B
Depreciation & Amortization14.18M10.33M10.58M11.01M16.45M
EBITDA(383.65M)(447.37M)(660.18M)(818.79M)(1.17B)
EBITDA Margin-203.6%-182.3%-216.3%-225.1%-193.2%
Operating Income(375.09M)(457.32M)(709.63M)(878.25M)(1.18B)
Operating Margin-199.0%-186.4%-232.5%-241.5%-194.0%
Interest Income174K11.08M42.13M53.31M60.66M
Interest Expense40.47M26.45M81.69M84.91M83.8M
Other Income / Expenses(61.32M)(22.83M)(37.39M)(31.81M)(95.02M)
Income Before Tax(436.41M)(480.15M)(747.01M)(910.07M)(1.27B)
Pre-Tax Margin-231.6%-195.7%-244.8%-250.2%-209.7%
Income Tax Expense(1.76M)1.38M2.56M3.71M5.03M
Net Income(434.65M)(481.53M)(749.57M)(913.77M)(1.28B)
Net Margin-230.6%-196.3%-245.6%-251.2%-210.5%
EPS (Basic)(3.88)(3.91)(5.34)(5.57)(6.41)
EPS (Diluted)(3.88)(3.91)(5.34)(5.57)(6.41)
Weighted Avg Shares112.11M123.04M140.43M164.04M213.64M
Weighted Avg Shares (Diluted)112.11M123.04M140.43M164.04M213.64M

Insmed Incorporated

NASDAQ:INSM

Intrinsic Alpha fair value

Locked

Current Price

$119.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.